Experienced in Pancreatic Islet Cell Tumor

Barbara Jarzab

Gliwice Branch, 
Gliwice, SL, PL 
Clinical Trials:Currently Recruiting for 2 Trials
Experienced in Pancreatic Islet Cell Tumor
Gliwice Branch, 
Gliwice, SL, PL 
OverviewLocationsClinical Research

Overview

Barbara Jarzab practices in Gliwice, Poland. Ms. Jarzab is rated as an Experienced expert by MediFind in the treatment of Pancreatic Islet Cell Tumor. Her top areas of expertise are Thyroid Cancer, Medullary Thyroid Carcinoma, Neuroendocrine Tumor, Papillary Thyroid Cancer, and Thyroidectomy.

Her clinical research consists of co-authoring 181 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 5 articles in the study of Pancreatic Islet Cell Tumor.

Gender
Female

Locations

Gliwice Branch, Gliwice, SL, Poland
Other Locations
Maria Sklodowska Curie National Research Institute of Oncology Gliwice Branch
Gliwice, SL, Poland
Gliwice Branch, Gliwice, SL 44102, Poland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized Registry Trial of Adjuvant Mitotane vs. Mitotane With Cisplatin/Etoposide After Primary Surgical Resection of Localized Adrenocortical Carcinoma With High Risk of Recurrence (ADIUVO-2 Trial)
A Randomized Registry Trial of Adjuvant Mitotane vs. Mitotane With Cisplatin/Etoposide After Primary Surgical Resection of Localized Adrenocortical Carcinoma With High Risk of Recurrence (ADIUVO-2 Trial)
Enrollment Status: Recruiting
Publish Date: October 01, 2025
Intervention Type: Other, Drug
Study Drugs: Cisplatin, Etoposide, Mitotane
Study Phase: Phase 3
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
Enrollment Status: Recruiting
Publish Date: May 01, 2025
Intervention Type: Genetic
An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Enrollment Status: Completed
Publish Date: June 19, 2025
Intervention Type: Drug
Study Drug: Levoketoconazole
Study Phase: Phase 3
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Cabozantinib, Vandetanib
Study Phase: Phase 3
A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Enrollment Status: Completed
Publish Date: November 08, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Prospective, Randomized, Double-blind, Multi-center Study of the Efficacy and Safety of Lanreotide Autogel®/Depot 120 mg Plus BSC vs. Placebo Plus BSC for Tumour Control in Subjects With Well Differentiated, Metastatic and/or Unresectable, Typical or Atypical, Lung Neuroendocrine Tumours
A Phase 3, Prospective, Randomized, Double-blind, Multi-center Study of the Efficacy and Safety of Lanreotide Autogel®/Depot 120 mg Plus BSC vs. Placebo Plus BSC for Tumour Control in Subjects With Well Differentiated, Metastatic and/or Unresectable, Typical or Atypical, Lung Neuroendocrine Tumours
Enrollment Status: Terminated
Publish Date: July 06, 2022
Intervention Type: Drug
Study Phase: Phase 3
Prospective Validation of the Molecular Classifier for the Fine Needle-based Assessment of Malignancy Risk in Thyroid Nodules
Prospective Validation of the Molecular Classifier for the Fine Needle-based Assessment of Malignancy Risk in Thyroid Nodules
Enrollment Status: Completed
Publish Date: September 05, 2021
View 5 Less Clinical Trials

180 Total Publications

Prospective study of metyrapone in endogenous Cushing's syndrome (PROMPT).
Prospective study of metyrapone in endogenous Cushing's syndrome (PROMPT).
Journal: European journal of endocrinology
Published: June 02, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Jarzab's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 19 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile